|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin GLP-3
Source: PubChem |
Jeri: YA⊃1;QGTFTSDYSI-L⊃2;LDKK⁴AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3; Tsarin kwayoyin halitta: C 221H 342N 46O68 Nauyin Kwayoyin: 4731 g/mol Lambar CAS: 2381089-83-2 PubChem CID: 171390338 Saukewa: LY3437943 |
▎ GLP-3 Bincike
Menene asalin bincike na GLP-3?
Asalin bincike na GLP-3 yana da alaƙa da alaƙa da ƙara matsananciyar lamuran duniya na kiba da metabolism, da kuma iyakancewar magungunan warkewa da ake da su: kiba da metabolism suna haifar da babbar barazana ga lafiyar jama'a, tare da yawan kiba na duniya da aka yi hasashen zai kai biliyan 4.005 nan da 2035 kuma adadin marasa lafiya na rayuwa yana ƙaruwa zuwa miliyan 592, wanda ya haifar da haɓakar lafiya a duniya. Multi-manufa agonist agonist peptides sun fito a matsayin mafita, iya hana kiba, zalunta metabolism, da kuma guje wa guba illa na data kasance kwayoyi, yin su a Trend a cikin ci gaban kiba da metabolism jiyya.
Menene tsarin aikin GLP-3?
Daidaita metabolism na makamashi ta hanyar kunnawa da yawa masu karɓa
GLP-3 agonist mai karɓar mai karɓa sau uku ne wanda ke yin niyya ga mai karɓar insulinotropic polypeptide mai karɓa (GIPR), mai karɓar glucagon-like peptide-1 (GLP-1R), da mai karɓar glucagon (GCGR). A lokaci guda yana kunna waɗannan masu karɓa guda uku, yana daidaita ƙarfin kuzari ta hanyoyi da yawa.
Ayyukan GIPR agonist:
GIP shine hormone mai ɓoye insulin na hanji wanda ƙwayoyin K hanji ke ɓoye kuma ana fitar dasu bayan abinci. GLP-3 yana kunna GIPR, yana haɓaka haɓakar insulin, haɓaka haɓakar insulin, kuma ta haka yana taimaka wa jiki sosai don sha da amfani da glucose, ta haka yana rage matakan glucose na jini. Bugu da ƙari, GIP na iya rinjayar metabolism na mai ta hanyar daidaita aikin adipocyte da rage yawan kitse [1].
Ayyukan agonist na GLP-1R:
GLP-1 shine hormone peptide wanda aka ɓoye ta ƙwayoyin L na hanji. Bayan kunna GLP-1R, GLP-3 yana haifar da fa'idodi daban-daban. Yana iya tayar da fitowar insulin ta hanyar dogaro da matakin glucose, wanda hakan zai rage matakan sukari na jini. Yana iya jinkirta zubar da ciki, ƙara koshi, da rage cin abinci. GLP-1R tashin hankali na iya aiki akan tsarin juyayi na tsakiya, yana daidaita ci da ma'aunin kuzari, ta haka yana taimakawa rage nauyi [2].
GCGR agonists:
Glucagon yawanci yana ƙara matakan glucose na jini, amma ƙarƙashin tasirin GLP-3, ƙwannafi na GCGR yana haifar da tasiri daban-daban. Yana inganta glycogenolysis da gluconeogenesis a cikin hanta. A ƙarƙashin tasirin haɗin GLP-3, jiki baya samun sauƙi mai sauƙi a cikin matakan glucose na jini amma a maimakon haka yana daidaita tsarin makamashi don ƙara raguwar mai, ta haka yana samun asarar nauyi da inganta haɓaka. GCGR agonist na iya rinjayar hanta lipid metabolism, rage yawan kitsen hanta [3].
Tasiri kan Tsarin Jiki masu alaƙa da Ciwon sukari
Ta hanyar aiki lokaci guda akan masu karɓa guda uku da aka ambata, GLP-3 yana tasiri tsarin tafiyar da rayuwa mai alaƙa da metabolism da yawa.
Tsarin glucose na jini:
Ta hanyar kunna GIPR da GLP-1R don haɓaka ƙwayar insulin, da kuma daidaita GCGR daidai, GLP-3 na iya rage matakan glucose na jini. Ana bayyana tasirinta na hypoglycemic lokacin da glucose na jini ya tashi, yayin da ba zai iya haifar da hypoglycemia ba yayin da glucose na jini ya zama al'ada, wanda ke da fa'ida ga sarrafa glucose na jini a cikin masu ciwon sukari [4]..
Gudanar da nauyi:
GLP-3 yana nuna tasiri mai mahimmanci a cikin sarrafa nauyi. Ta hanyar kunna GLP-1R, yana rage jinkirin zubar da ciki, yana ƙara jin daɗi, kuma yana rage cin abinci; ta hanyar daidaita metabolism na mai, yana inganta rushewar kitse da kashe kuzari, ta haka ne ke samun asarar nauyi. Gwajin asibiti sun nuna cewa marasa lafiya masu kiba ko masu kiba da aka bi da su tare da GLP-3 sun sami babban asarar nauyi a cikin wani ɗan lokaci [5,6].
Tsarin lipid:
Jiyya na GLP-3 yana inganta bayanan lipid na marasa lafiya. Yana rage triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), da kuma low-density lipoprotein cholesterol matakan (VLDL-C), yayin da kuma daidaita apolipoproteins, kamar rage apolipoprotein B (apoB) da apolipoprotein C -III (apoprotein da ke hade da atherosclerosis, rage yawan lipoprotein da lipoproteins). inganta lafiyar zuciya [7].
Inganta hanta lipid metabolism:
Ga marasa lafiya da cututtukan hanta maras-giya (NAFLD) waɗanda ke da alaƙa da tabarbarewar rayuwa, GLP-3 yana rage yawan kitsen hanta. A cikin gwaje-gwajen da suka dace na asibiti, marasa lafiya da aka bi da su tare da allurai daban-daban na GLP-3 sun nuna raguwar dangi mai yawa a cikin abun ciki mai hanta idan aka kwatanta da tushe, yana nuna cewa GLP-3 yana da tasiri mai kyau na tsari akan metabolism na mai, wanda ke da fa'ida don haɓaka aikin hanta [3]..
Hoto na 1 GLP-3 hanyoyin aiki [8].
Menene aikace-aikacen GLP-3?
Maganin Kiba:
Kiba ya zama babban batun kiwon lafiyar jama'a a duniya, wanda ke da alaƙa da farawa da ci gaban cututtuka daban-daban. GLP-3 ya nuna tasiri mai mahimmanci a cikin maganin kiba. Marasa lafiya masu kiba da aka yi musu magani tare da GLP-3 sun sami gagarumin raguwar nauyin jiki. A cikin nazarin kiba na makonni 48 na Phase 2, marasa lafiya da aka bi da su tare da 8mg da 12mg na GLP-3 sun sami raguwar nauyi na 22.8% da 24.2%, bi da bi. A cikin wani Mataki na 2 makafi biyu, bazuwar, gwajin sarrafa wuribo, marasa lafiya a cikin ƙungiyoyin kashi daban-daban sun sami nau'ikan asarar nauyi a makonni 24 da makonni 48. Ƙungiyar 12mg ta sami asarar nauyi na 24.2% a makonni 48, yayin da ƙungiyar placebo kawai ta ga raguwar -2.1%. GLP-3 yadda ya kamata yana rage nauyin jiki a cikin marasa lafiya masu kiba, yana ba da sabon kayan aiki mai ƙarfi don maganin kiba. Maganin GLP-3 don kiba ba kawai yana rage nauyin jiki ba amma yana iya inganta wasu al'amurran kiwon lafiya da ke da alaƙa da kiba, kamar rage damuwa da haɗin gwiwa da kuma kawar da alamun cututtuka na haɗin gwiwa da ke da alaka da kiba ta hanyar asarar nauyi; Rage kiba na iya taimakawa inganta matsalolin da ke da alaƙa da kiba kamar su bacci [3,6].
Nau'in 2 Metabolism Jiyya:
Nau'in 2 metabolism cuta ce ta yau da kullun wacce ke da alaƙa da juriya na insulin da rashin isasshen ƙwayar insulin. GLP-3 yana da yuwuwar ƙimar aikace-aikacen a cikin jiyya na nau'in 2 metabolism. Yana motsa ƙwayar insulin ta hanyar kunna mai karɓar GLP-1, yana inganta juriya na insulin, yana rage matakan glucose na jini. Har ila yau, tasirinsa na rage nauyi yana taimakawa wajen inganta yanayin marasa lafiya na nau'in 2 na metabolism, saboda kiba yana da mahimmancin haɗari ga nau'in 2 na metabolism, kuma asarar nauyi na iya haɓaka haɓakar insulin, yana ƙara taimakawa wajen sarrafa glucose na jini. A cikin binciken da ya shafi marasa lafiya tare da nau'in 2 na metabolism, GLP-3 ya haifar da asarar nauyi mai yawa da kuma raguwa mai mahimmanci a matakan haemoglobin A1c (HbA1c), tare da HbA1c yana raguwa da 1.64% idan aka kwatanta da placebo. Wannan yana nuna cewa GLP-3 ba wai kawai yana sarrafa matakan glucose na jini yadda ya kamata ba amma yana inganta yanayin gabaɗayan marasa lafiya tare da nau'in metabolism na nau'in 2 ta hanyoyi da yawa, gami da asarar nauyi, ta haka yana haɓaka ingancin rayuwarsu [6]..
Maganin ciwon hanta mara-giya (NAFLD):
NAFLD wani rauni ne na hanta da ke haifar da danniya wanda ke da alaƙa da juriya na insulin da raunin kwayoyin halitta, wanda ya ƙunshi nau'ikan yanayi ciki har da hanta mai sauƙi mara-giya, steatohepatitis mara giya, da cirrhosis masu alaƙa. GLP-3 yana nuna yuwuwar yuwuwar a cikin jiyya na NAFLD. A cikin bazuwar, makafi biyu, gwajin sarrafa placebo wanda ya haɗa da mahalarta tare da cututtukan hanta da ke da alaƙa da cututtukan hanta da cututtukan hanta da abun ciki na hanta ≥10%, a cikin makonni 24, ma'anar canjin dangi a cikin abun ciki mai hanta daga tushe ya bambanta sosai a cikin rukunin GLP-3: -81.4% a cikin rukunin 8mg, -82.4% a cikin rukunin + 10.bo. Wannan yana nuna cewa GLP-3 na iya rage yawan kitsen hanta yadda ya kamata, wanda ke da mahimmancin mahimmanci don haɓaka cututtukan hanta na marasa lafiya na NAFLD. Yana ɗaukar alkawari azaman sabon zaɓi na magani don NAFLD, mai yuwuwar rage jinkirin ci gaban cuta da rage haɗarin rikitarwa mai tsanani kamar cirrhosis [3].
Kammalawa
GLP-3 yana nuna yuwuwar yuwuwar haɓaka yanayin cututtukan hanta na marasa lafiya na NAFLD, yin aiki ta hanyoyi da yawa ciki har da daidaita ƙarfin kuzari, haɓaka juriya na insulin, tasirin anti-mai kumburi, da daidaita metabolism na lipid.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Rosenstock, J fitaccen malami ne wanda aikinsa ke da alaƙa da alaƙa da manyan cibiyoyi da yawa, gami da Jami'ar Texas Southwestern Medical Center, Jami'ar Texas Dallas, da Cibiyar VIGOR ta Kanada. Bincikensa ya mamaye fannoni da yawa kamar Endocrinology & Ciwon sukari, Gabaɗaya & Magungunan Ciki, Tsarin zuciya da jijiyoyin jini, Pharmacology & Pharmacy, da Bincike & Magungunan Gwaji. Gudunmawar da ya bayar ga al'ummar ilimi ta sami karbuwa sosai, kamar yadda aka nuna ta hanyar zaɓen da ya maimaita a matsayin 'Mai bincike mai zurfi a fagen ilimin likitanci' daga 2017 zuwa 2024, yana nuna babban matsayinsa da babban tasiri a binciken likitancin asibiti. An jera Rosenstock J a cikin ambaton ambaton [4].
